Director Robert Chess filed a Form 144 notice of proposed sale with the U.S. Securities and Exchange Commission on November 19, 2026, disclosing plans to sell 15,000 shares of Twist Bioscience Corp common stock through Fidelity Brokerage Services LLC.

Key Highlights

  • Seller and role: Robert Chess, a Director of Twist Bioscience Corp, is the person for whose account the securities are to be sold.
  • Shares proposed for sale: 15,000 shares of Twist Bioscience Corp common stock, with an aggregate market value of $1,811,250.00 as stated in the filing.
  • Approximate date of sale: November 19, 2026, to be executed on NASDAQ.
  • Source of shares: The shares were acquired on March 24, 2014, via stock option exercise from the issuer, with payment made in cash on the same date.
  • Rule 10b5-1 plan: The filing indicates a plan adoption or giving of instruction date of August 19, 2026.
  • Trust allocation: According to the filing's remarks, 7,000 of the shares being sold were from the Chess 1997 Trust, of which Robert B. Chess is an Account Stakeholder and a Trustee.
  • Shares outstanding: The filing reports 68,178,692 shares of common stock outstanding.

Robert Chess Form 144 Filing: Proposed Sale Details for Twist Bioscience

According to the Form 144 filed on November 19, 2026, Robert Chess, identified as a Director of Twist Bioscience Corp (NASDAQ:TWST), has provided notice of a proposed sale of 15,000 shares of the company's common stock. The filing lists Fidelity Brokerage Services LLC, located at 900 Salem Street, Smithfield, RI 02917, as the named broker for the transaction. The aggregate market value of the proposed sale is stated as $1,811,250.00 in the filing.

The filing discloses that the 15,000 shares to be sold were originally acquired on March 24, 2014, through a stock option exercise from the issuer, with the nature of payment listed as cash on that same date. The filing reports no securities sold by the filer during the past three months. The proposed sale is intended to be conducted on NASDAQ, and the filing indicates that Chess is relying on a Rule 10b5-1 plan or instruction adopted on August 19, 2026.

In the remarks section, the filing states: "Of todays trades 7000 shares were sold from the Chess 1997 Trust, of whom Robert B Chess is an Account Stakeholder and a Trustee." The notice was signed by Daniel Tucci, as a duly authorized representative of Fidelity Brokerage Services LLC, acting as attorney-in-fact for Robert Chess. The filing lists Twist Bioscience Corp's address as 681 Gateway Blvd., South San Francisco, California 94080, with SEC File Number 001-38720.

What Was Disclosed

Twist Bioscience Corp Director Robert Chess filed a Form 144 on November 19, 2026, disclosing a proposed sale of 15,000 common shares with an aggregate market value of $1,811,250.00, acquired via stock option exercise in 2014, under a Rule 10b5-1 plan adopted August 19, 2026.